7820 Stock Chart & Stats
€1.50
-€0.03(-2.78%)
At close: 4:00 PM EST
€1.50
-€0.03(-2.78%)
Day’s Range― - ―
52-Week Range€1.10 - €3.03
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€13.41M
Enterprise Value€151.30
Total Cash (Recent Filing)€27.94M
Total Debt (Recent Filing)€5.40M
Price to Earnings (P/E)―
Beta0.05
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.57
Shares Outstanding8,497,797
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.11
Price to Sales (P/S)0.00
P/FCF Ratio-4.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€3.89M
Bulls Say, Bears Say
Bulls Say
Unmet Medical NeedThe product addresses a severe condition with limited treatment options. If validated and approved, an artificial heart could serve patients who cannot receive a transplant or need an alternative to existing mechanical support.
Low LeverageModest debt reduces near-term balance-sheet pressure and leaves more flexibility than a highly leveraged structure. This can help preserve strategic options while the company funds development and pursues regulatory progress.
Multiple Future Monetization ChannelsThe prospective business model extends beyond one-time device sales. Recurring components, support services, and potential licensing or distribution arrangements could diversify future revenue and improve commercial scalability if approvals are achieved.
Bears Say
Pre-revenue Business ModelThe company has not yet demonstrated a durable commercial ramp or repeatable customer demand. Until regulatory and commercialization milestones are reached, the investment case depends mainly on future execution rather than established operating revenue.
Persistent Operating LossesSustained losses reflect continuing research, development, and operating costs without sufficient revenue to absorb them. This limits internal reinvestment capacity and increases the importance of successful product development and eventual market adoption.
Ongoing Funding DependencePersistent cash outflows mean the business is not self-funding and must rely on external capital or other financing sources. Continued funding needs can constrain development plans and increase dilution risk if equity financing remains necessary.
7820 FAQ
What was Scandinavian Real Heart AB’s price range in the past 12 months?
Scandinavian Real Heart AB lowest stock price was €1.09 and its highest was €3.03 in the past 12 months.
What is Scandinavian Real Heart AB’s market cap?
Scandinavian Real Heart AB’s market cap is €13.41M.
When is Scandinavian Real Heart AB’s upcoming earnings report date?
Scandinavian Real Heart AB’s upcoming earnings report date is Nov 12, 2026 which is in 57 days.
How were Scandinavian Real Heart AB’s earnings last quarter?
Scandinavian Real Heart AB released its earnings results on Aug 26, 2026. The company reported -€0.254 earnings per share for the quarter.
Is Scandinavian Real Heart AB overvalued?
According to Wall Street analysts Scandinavian Real Heart AB’s price is currently Overvalued.
Does Scandinavian Real Heart AB pay dividends?
Scandinavian Real Heart AB does not currently pay dividends.
What is Scandinavian Real Heart AB’s EPS estimate?
Scandinavian Real Heart AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scandinavian Real Heart AB have?
Scandinavian Real Heart AB has 8,497,797 shares outstanding.
What happened to Scandinavian Real Heart AB’s price movement after its last earnings report?
Scandinavian Real Heart AB reported an EPS of -€0.254 in its last earnings report. Following the earnings report the stock price went up 0.629%.
Which hedge fund is a major shareholder of Scandinavian Real Heart AB?
Currently, no hedge funds are holding shares in DE:7820
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scandinavian Real Heart AB
Scandinavian Real Heart AB (Publ), a Swedish enterprise established in 2007, specializes in the innovation and production of artificial heart devices. The company's core focus is the Realheart TAH, a total artificial heart engineered specifically to address severe cases of heart failure. Beyond this central project, their product portfolio also encompasses medical solutions such as the RealVAD, PulsePump, and Sternal Prosthesis. The firm operates from its base in Västerås, Sweden.